BioStem Technologies, Inc. has signed an important agreement and is issuing new shares.

Sep 30, 2026, 4:50 PM ETNew sharesRead the original at SEC EDGAR

Bad for BSEM

BioStem missed the $10 million payment due after Catalyze received FDA clearance, and discussions continue. Its private share-and-warrant sale may bring in cash, but the filing gives no amount, so the overdue bill weighs more.

BSEM · BioStem Technologies, Inc.

AI read · Bad for BSEM

The AI's read

The missed payment leaves BioStem with an overdue $10 million bill after the product received FDA clearance. The company says it is still discussing when and how to pay. A private sale of shares and warrants may bring in cash, but the filing gives no amount, so it does not show that the bill is covered.

Get alerts for BSEM

Follow BioStem Technologies, Inc. (BSEM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BSEM

Free on the App Store and Google Play, or on the web.